(Washington, DC) -- The FDA is rethinking the approval of certain asthma medication due to the drugs' high risks.
Evidence was found showing an increased risk of asthma attacks and asthma-related deaths.
The FDA's Drug-Safety staff is recommending pulling approval of the drugs for the treatment of lung disease and for treating asthma in children and adults.
The administration is expected to decide the matter before the end of the week.
Some of the drugs in question are Advair, Serevent, Symbicort and Foradil.
(Copyright 2008 by Newsroom Solutions)